Natalizumab

Assessment report

Scientific discussion" about Tysabri (natalizumab), EMEA 2006.

"The environmental risk assessment of natalizumab followed primarily the draft of guidelines related to this issue. From the results obtained, it is concluded that natalizumab for I.V.injection is of no immediate risk to the environment and no proposals for labelling provisions are necessary to reduce any potential environmental risks."

Fass environmental information

Fass environmental information for Tysabri (natalizumab) from Biogen Sweden (downloaded 2020-08-12).

Risk

The use of amino acids, proteins and peptides is not considered to have any environmental impact.

Detailed information

According to the European Medicines Agency guideline on environmental risk assessments for pharmaceuticals (EMA/CHMP/SWP/4447/00), vitamins, electrolytes, amino acids, peptides, proteins, carbohydrates, lipids proteins, vaccines and herbal medicinal products are exempted because they are unlikely to result in significant risk to the environment.